Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL
October 07, 2019 06:46pm
By Marcelo C. Pasquini, MD
Toni K. Choueiri, MD, discusses the current role of immunotherapy in the treatment of patients with renal cell carcinoma.
Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine at Harvard Medical School, Dana-Farber Cancer Institute, discusses the current role of immunotherapy in the treatment of patients with renal cell carcinoma (RCC).
Over the last decade, a variety of cytokine, VEGF, and mTOR inhibitors have been available in RCC. Now, Choueiri says, immunotherapy is coming back in the form of checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4.